Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PRO-SCT

Financiado

PROducing Stem Cells for improved Treatment of patients

The market for stem cells is growing fast as new possibilities for stem cell treatments evolve. Today stem cell treatments are often based on a process where the patient’s own cells are grown for weeks, and thereafter patients are... ver más

30/11/2019

CELL2CURE

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

CELL2CURE APS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 70% 100%

2 Participantes

CELL2CURE

50.00K€ | Lider

XAMPINYONS MALLORQUINS

279.80K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2019-05-06
Fecha Fin: 2019-11-30

Líder del proyecto

CELL2CURE APS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Descripción del proyecto The market for stem cells is growing fast as new possibilities for stem cell treatments evolve. Today stem cell treatments are often based on a process where the patient’s own cells are grown for weeks, and thereafter patients are treated with their own stem cells. This process limits a wider use of these treatments, as it is a slow and costly procedure. The key novelty in the PRO-SCT project is that it is the first fully compliant industrially applicable platform capable of large-scale stem cell production from healthy donor adipose tissue, making ready-to-use stem cells available whenever and wherever needed. Cell2Cure has leading competencies in the areas of producing, storing, and distributing stem cells from donors, and clinical and regulatory know-how in the use of cell-based therapies. C2C stem cells will be manufactured in large batches, stored frozen in vials that can be ready for use in a few minutes before treatment. The C2C technology uses state-of-the-art automated closed bioreactor systems with animal component free expansion of allogeneic cells and long-term cryopreservation of ready-to-use vials. Compared to today's stem cell treatment, this allows for scalability and easy distribution - improving availability and reducing both cost and time to treatment. With a strong scientific basis, Cell2Cure has made significant progress in the understanding of donor derived stem cells in the development of treatments for heart failure. Clinical trials have shown that C2C stem cells are safe, usable and have promising clinical effects. The aim of the PRO-SCT project is to develop a strong commercial and operational position for Cell2Cure to move from small scale to large scale capacity and unlock a new global market for adipose tissue derived donor stem cells. To do this successfully, the support of EU-Instrument phase I will be of immense importance. Cell2Cure has firm control of the intellectual property with a broadly covering WO-patent application in place.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores